NEW YORK, March 18, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Cell Therapeutics, Inc. (NASDAQ: CTIC), Intrexon Corporation (NYSE:
XON), Chimerix, Inc. (NASDAQ: CMRX), Receptos, Inc. (NASDAQ: RCPT),
andRevance Therapeutics, Inc. (NASDAQ: RVNC). Private wealth
members receive these notes ahead of publication. To reserve
complementary membership, limited openings are available at:
http://www.AnalystsReview.com/register
Cell Therapeutics, Inc. Analyst Notes
On March 3, 2014, Cell
Therapeutics, Inc. (CTI) announced the initiation of a Phase 3
clinical trial, PERSIST-2, evaluating pacritinib. Pacritinib is a
novel investigational JAK2/FLT3 inhibitor, in patients with
myelofibrosis whose platelet counts are less than or equal to
100,000 per microliter (uL). "With the initiation of the PERSIST-2
trial, we believe that the registration program for pacritinib is
on track for a potential NDA submission in the latter part of
2015," said James A. Bianco, MD,
President and CEO of CTI. "We have seen meaningful clinical
benefits and good tolerability with pacritinib in myelofibrosis
patients in Phase 2 trials without apparent drug-related
thrombocytopenia or anemia. As such, we have had strong interest in
site participation for this trial and will work diligently to
activate these sites over the next several months." The trial is
expected to enroll up to 300 patients in North America, Europe, Australia and New
Zealand within 12 to 14 months. The full analyst notes on
Cell Therapeutics, Inc. are available to download free of charge
at:
http://www.AnalystsReview.com/03182014/CTIC/report.pdf
Intrexon Corporation Analyst Notes
On March 7, 2014, Intrexon Corp.
(Intrexon) announced that it has completed the acquisition of
Medistem, Inc., a pioneer in the development of Endometrial
Regenerative Cells. Under the terms of the agreement, Medistem
stockholders will receive in exchange for each share of Medistem
common stock $0.27 in cash and
$1.08 worth of Intrexon common stock,
or approximately 0.03920 shares. This is based on the 20-day
volume-weighted average price of Intrexon's common stock
immediately prior to closing, subject to adjustment pursuant to the
terms of the merger agreement. The full analyst notes on Intrexon
Corporation are available to download free of charge at:
http://www.AnalystsReview.com/03182014/XON/report.pdf
Chimerix, Inc. Analyst Notes
On March 7, 2014, Chimerix Inc.
(Chimerix) reported its Q4 2013 and full-year 2013 financial
results. For the quarter, the Company reported a net loss of
$8.2 million or $0.31 per basic and diluted share,compared to a
net loss of $4.3 million or
$3.90 per basic and diluted share in
Q4 2012. Revenues totaled $879,000,
compared to $3.6 million in Q4 2012.
For full-year 2013, net loss was $36.4
million or $3.65 per basic and
diluted share, compared to net loss of $4.4
million or $5.75 per basic and
diluted share in 2012. Revenues were $4.4
million, compared to $33.7
million in 2012. The decrease in revenues were attributable
to a decrease in reimbursable expenses associated with Chimerix's
ongoing contract with BARDA in 2013, and the receipt of an upfront
license payment related to Chimerix's collaboration and license
arrangement with Merck in 2012. The full analyst notes on Chimerix,
Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03182014/CMRX/report.pdf
Receptos, Inc. Analyst Notes
On March 5, 2014, Receptos, Inc.
(Receptos) reported its Q4 2013 and full-year 2013 (period ended
December 31, 2013) financial results.
For the quarter, the Company reported net loss of $15.2 million, or $0.86 per common share, compared to a net loss of
$4.5 million, or $3.08 per common share, in Q4 2012. Total
revenues were $773,000, compared to
$3.8 million in Q4 2012. Revenue
during these periods consisted primarily of amortization of
up-front fees and milestone payments, and development funding
received from our collaborative arrangements. Fiscal year 2013 net
loss was as $50.4 million, or
$4.23 per common share, compared to a
net loss of $17.7 million, or
$13.73 per common share, in 2012.
Total revenues were $4.6 million
compared to $8.6 million in 2012. The
full analyst notes on Receptos, Inc. are available to download free
of charge at:
http://www.AnalystsReview.com/03182014/RCPT/report.pdf
Revance Therapeutics, Inc. Analyst Notes
On March 12, 2014, Revance
Therapeutics, Inc. (Revance) announced the schedule of its earnings
release and conference call. The Company will report its Q4 2013
and full-year 2013 financial results on March 26, 2014, Wednesday, after the close of
market. The Company's management will also host a conference call
and live internet webcast on the same day at 1:30 p.m. PT or 4:30 p.m.
ET to discuss the results as well as provide business
updates. The webcast will be available in the Investor Relations
section on the Company's website for 30 days following the
completion of the call. The full analyst notes on Revance
Therapeutics, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03182014/RVNC/report.pdf
About Analysts Review
We provide our members with a simple and reliable way to
leverage our economy of scale. Most investors do not have time to
track all publicly traded companies, much less perform an in-depth
review and analysis of the complexities contained in each
situation. That's where Analysts Review comes in. We provide a
single unified platform for investors' to hear about what matters.
Situation alerts, moving events, and upcoming opportunities.
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
-
For any urgent concerns or inquiries,
please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
http://www.AnalystsReview.com
SOURCE Analysts Review